Medicine guide
Dynepo
·
- Prescription status not stated
- Blood, clotting and anaemia
- Active substance
- Epoetin delta
- Used in
- Blood, clotting and anaemia
- Made by
- Shire Pharmaceutical Contracts Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Dynepo is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult patients. It may be used in patients on dialysis and in patients not on dialysis.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Shire Pharmaceutical Contracts Limited |
|---|---|
| Active substance | Epoetin delta |
| Used in | Blood, clotting and anaemia |
| Classification | B03XA · Blood, clotting and anaemia |
| Authorised on | 2002-03-18 |
| Last updated by the regulator | 2009-04-23 |
| EMA product number | EMEA/H/C/000372 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).